National Healthcare director receives 7,500 stock options
National Healthcare Corp director Robert G. Adams reported a new stock option grant.
Rhea-AI Filing Summary
National Healthcare Corp director Robert G. Adams reported a new stock option grant. He received options covering 7,500 shares of common stock at an exercise price of $171.42 per share, expiring on May 6, 2031.
The options were granted on May 7, 2026 under the company’s 2020 Omnibus Equity Incentive Plan, with no cash paid for the grant. The filing also lists existing option awards from 2022–2025 and indirect holdings of common stock in a trust and a partnership, but no open‑market share purchases or sales.
Positive
- None.
Negative
- None.
Insights
Routine option grant increases director’s long‑term equity exposure.
Director Robert G. Adams received stock options on May 7, 2026 for 7,500 shares of National Healthcare Corp common stock at an exercise price of $171.42. The options were issued under the 2020 Omnibus Equity Incentive Plan as a compensation award.
The filing shows no open‑market buying or selling; the main economic event is this grant. Adams also retains several prior option grants with exercise prices between $55.75 and $96.03 expiring from 2027 to 2030, plus indirect holdings in a trust and partnership. Overall, the activity appears routine and compensation‑related rather than a trading signal.
Insider Trade Summary
Grant/Award: 7,500 shares
Grant/Award
7 txns
Insider
ADAMS ROBERT G
Role
Director
| Type | Security | Shares | Price | Value |
|---|---|---|---|---|
| Grant/Award | Option to Purchase Common Stock [2026 Grant] | 7,500 | $0.00 | $0.00 |
| holding | Option to Purchase Common Stock [2022 Grant] | -- | -- | -- |
| holding | Option to Purchase Common Stock [2023 Grant] | -- | -- | -- |
| holding | Option to Purchase Common Stock [2024 Grant] | -- | -- | -- |
| holding | Option to Purchase Common Stock [2025 Grant] | -- | -- | -- |
| holding | Shares of Common Stock - Partnership | -- | -- | -- |
| holding | Shares of Common Stock - Trust I | -- | -- | -- |
Holdings After Transaction:
Option to Purchase Common Stock [2026 Grant] — 7,500 contracts (Direct);
Option to Purchase Common Stock [2022 Grant] — 7,500 contracts (Direct);
Option to Purchase Common Stock [2023 Grant] — 7,500 contracts (Direct);
Option to Purchase Common Stock [2024 Grant] — 7,500 contracts (Direct);
Option to Purchase Common Stock [2025 Grant] — 7,500 contracts (Direct);
Shares of Common Stock - Partnership — 430,341 shares (Indirect, General Partner);
Shares of Common Stock - Trust I — 13,579 shares (Indirect, Trustee)
Footnotes (1)
- F1. These stock options were granted pursuant to the 2020 Omnibus Equity Incentive Plan on May 7, 2026. The grant and exercise of these stock options are exempt from Section 16(b) pursuant to Rule 16b-3(d).
Key Figures
2026 option grant size: 7,500 shares
2026 grant exercise price: $171.42 per share
2022 option grant underlying shares: 7,500 shares
+4 more
7 metrics
2026 option grant size
7,500 shares
Underlying common shares for 2026 stock option award
2026 grant exercise price
$171.42 per share
Exercise price for 2026 option grant expiring May 6, 2031
2022 option grant underlying shares
7,500 shares
Option to purchase common stock [2022 Grant] underlying shares
2022 grant exercise price
$69.19 per share
Exercise price for 2022 option grant expiring May 4, 2027
2023 grant exercise price
$55.75 per share
Exercise price for 2023 option grant expiring May 3, 2028
Indirect partnership holdings
430,341 shares
Common stock held indirectly as general partner of a partnership
Indirect trust holdings
13,579 shares
Common stock held indirectly as trustee of a trust
Key Terms
2020 Omnibus Equity Incentive Plan, Section 16(b), Rule 16b-3(d), stock options, +1 more
5 terms
2020 Omnibus Equity Incentive Plan financial
"These stock options were granted pursuant to the 2020 Omnibus Equity Incentive Plan on May 7, 2026."
Section 16(b) regulatory
"The grant and exercise of these stock options are exempt from Section 16(b) pursuant to Rule 16b-3(d)."
A federal rule that requires company insiders—like officers, directors and large shareholders—to return any profits made from buying and selling the company’s stock within a six-month window. It matters to investors because it discourages short-term trades that could exploit non-public information and helps protect outside shareholders by creating a simple, enforceable way to recover unfair gains, much like a rule stopping someone from flipping a limited-edition item for quick profit after getting early access.
Rule 16b-3(d) regulatory
"The grant and exercise of these stock options are exempt from Section 16(b) pursuant to Rule 16b-3(d)."
Rule 16b-3(d) is a narrow SEC safe-harbor that shields company insiders (officers, directors and large shareholders) from liability for short‑swing profits when their buys or sells of company stock are made under a pre-established, written plan or contract that removes the insider’s ability to time trades. For investors, this matters because it permits predictable, automated insider transactions — like scheduled sales for diversification or payroll withholding — without triggering forced disgorgement, so such planned trades are treated differently from opportunistic insider trading.
stock options financial
"These stock options were granted pursuant to the 2020 Omnibus Equity Incentive Plan on May 7, 2026."
Stock options are agreements that give a person the right to buy or sell a company's stock at a specific price within a certain time frame. They are often used as a reward or incentive, similar to a coupon that can be used later if the stock price rises, allowing the holder to make a profit.
indirect ownership financial
"Shares of Common Stock - Partnership, indirect ownership as General Partner."
FAQ
AI-generated questions and answers. How Rhea-AI works. Not financial advice.
What did Robert G. Adams report in this Form 4 for NATIONAL HEALTHCARE CORP (NHC)?
Robert G. Adams reported receiving a stock option grant for 7,500 shares of National Healthcare Corp common stock. The award is a compensation-related option and not an open-market trade, with terms set under the company’s 2020 Omnibus Equity Incentive Plan.
How large is the new stock option grant reported by NHC director Robert G. Adams?
The new grant covers options on 7,500 shares of National Healthcare Corp common stock. These options give Adams the right to buy those shares at a fixed exercise price in the future, adding to his existing portfolio of equity-based compensation awards.
What is the exercise price and expiration of the 2026 option grant at National Healthcare Corp?
The 2026 option grant to Robert G. Adams has an exercise price of $171.42 per share and expires on May 6, 2031. This means he can choose to buy up to 7,500 shares at that price any time before the expiration date, subject to vesting terms.
Did Robert G. Adams buy or sell any NHC common stock in the market in this filing?
The filing does not show any open-market purchases or sales of National Healthcare Corp common stock by Robert G. Adams. It instead records a grant of stock options as compensation and lists his existing option positions and indirect share holdings in a trust and partnership.
What other equity awards and holdings does Robert G. Adams have in NHC according to this Form 4?
Adams holds prior stock option grants from 2022 through 2025, each covering 7,500 underlying shares with exercise prices between $55.75 and $96.03. He also has indirect ownership of common stock through a trust holding 13,579 shares and a partnership holding 430,341 shares.
Under which plan was the new NHC stock option grant to Robert G. Adams issued?
The new stock option grant was issued under National Healthcare Corp’s 2020 Omnibus Equity Incentive Plan. The footnote states the grant on May 7, 2026 and notes that the grant and any exercise are exempt from Section 16(b) under SEC Rule 16b-3(d).
AI-generated analysis. How Rhea-AI works. Not financial advice.
